Today’s AI Top Pick: KC

9/1/2026 · Swing Setup screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

View the live KC price forecast →

Today's pick · Swing SetupKCBUY NOW8.4 / 109/1/2026

Kingsoft Cloud (KC) is the cleanest multi-timeframe setup in the pool at $10.35. Every forecast horizon on every timeframe is positive: 4h fc_short +19.6% / fc_mid +25.3% / fc_long +58.1%, 1d fc_short +20.4% / fc_mid +33.6% / fc_long +34.8%, and 1wk fc_long +13.5%. Kronos bullish_prob is 1.0 with near_term_bullish also 1.0 — that combination is rare in this pool (only XPEV, RARE and LUNR share it, and each of them has a red flag KC doesn't). Crucially, KC is NOT chased. On the daily it sits at just 4.12% of its 21-bar range with a -20.89% drawdown from the 21-bar high, and on the weekly it's 18.35% of range with a -43.18% dd. That's the textbook 'washed out but turning' setup — the 4h has already begun to lift (+20.5% over the last 21 bars, position 88.5%) which is the first sign of a base breaking upward, while daily/weekly still have plenty of room to run. You are buying pullback within a re-emerging uptrend, not chasing a top. Fundamentals aren't a moonshot but they're defensible: sales +34.9% YoY, EPS next-Y +60.5%, targetUpsidePct +89.2%, analyst recom 1.06 (essentially the strongest buy rating in the whole pool), debt/equity 0.77 and no ridiculous fwdPe like XPEV's 514. News tape is confirming, not undermining: 'losses narrowing' (Benzinga 8/25) and Zacks calling for +60% rally (8/21). No dilution, no legal, no short-seller report. Why today vs waiting: the 4h has already begun to break higher out of the base while the daily/weekly are still deeply in range — that's the sweet spot before daily confirmation drags price to the middle/upper range and worsens your entry. Waiting risks losing the -20% daily drawdown discount. I passed on XPEV (bigger forecasts but Barclays just cut PT to $14, fwdPe 514, operating losses deepening) and on RARE (FDA approval is priced in, near_term_bullish is 0).

KC forecast chart
Entry zone
$10.15–$10.55 (scale in around current $10.35; add on any dip to $10.00)
Stop loss
$9.20 (below the 21-bar daily low; ~-11% risk)
First target
$12.40 (aligns with 1d fc_mid +20% and reclaim of mid-range)
Longer target
$15.50–$16.30 (aligns with 4h fc_long +58% and 1d fc_long +34.8%)
Risks
  • China ADR / VIE regulatory risk — a single policy headline can gap a name like KC 10-15% overnight regardless of setup
  • Profit margin still -5.49% and operMargin -3.19%; if the 'losses narrowing' narrative reverses next quarter the multi-TF forecast will re-rate quickly
  • Weekly forecast short-term is -0.78% — near-term chop is likely; the 4h could give back gains before daily follow-through
  • Institutional ownership is just 4.85%, meaning thin sponsorship and higher volatility on flow shocks
  • Debt/equity 0.77 is elevated for an unprofitable name — refinancing/dilution risk if the tape rolls over
Honorable mentions
XPEVLargest forecast magnitude in the pool (4h fc_long +97%, 1d fc_long +56%, 1wk fc_long +62%) with bullish_prob 1 and pos_in_range 0% — but Barclays just lowered PT to $14 and fwdPe of 514 with deepening auto losses (Insider Monkey 8/27) makes it a #2, not a #1. Great trading candidate on a bounce setup.
RAREFDA gene-therapy approval is a real catalyst and JPM raised PT to $80 vs $25.43 current — bullish_prob 1 and 1wk fc_long +53%. Downgraded to #3 because near_term_bullish is 0 and profitMargin -81.8%; better as a BUY_PULLBACK.
Full ranking (16)
#SymbolVerdictScoreRead
1KCBUY NOW8.4All-timeframe green forecasts, deep daily/weekly pullback, recom 1.06, positive news tape — cleanest setup in the pool.
2XPEVBUY NOW7.8Biggest forecast magnitudes (fc_long +97% on 4h) at bottom of 4h/1wk range, but Barclays PT cut and fwdPe 514 cap conviction.
3RAREBUY PULLBACK7.2FDA approval + JPM/Wells target hikes to $50–$80, 1wk fc_long +53%, but near_term_bullish 0 argues for waiting for a 4h flush.
4LUNRBUY PULLBACK6.5Bullish_prob 1 and 1d fc_mid +21.7%, deeply washed out (-65% weekly dd), but 1wk fc_long -45% is a warning to size small.
5BTDRWAIT6.0Strong Malaysia AI cloud catalyst and 1d fc_long +34.7%, but 1wk forecasts are negative and 39% short float makes it a squeeze/dump lottery.
6ATATBUY PULLBACK5.6Best pure fundamentals in the pool (PE 17, ROE 58.8, PEG 0.64) but 4h position 96.8% of range and 1wk fc_long -17.7% — wait for a reset.
7GLXYWAIT5.2Constructive daily forecast (+18.3% long), but bullish_prob is null and only two timeframes — no confirmation edge.
8GRNDWAIT3.8Great fundamentals (ROE 108, margin 18.8%) but bullish_prob 0 and all forecast horizons negative — screen name only.
9DLOWAIT3.5Solid Q2 print and Truist raised PT to $18, but bullish_prob 0 and every forecast horizon points down; wait for tape to turn.
10TGTXAVOID3.0Buyout rumor pop already reflected — 4h fc_short -49% and 1d fc_short -44% signal the fade is on.
11ARISAVOID2.8Up 130% YoY, at 76.7% of weekly range, 1wk fc_long -72% — classic parabolic exhaustion after Simply Wall St 'fairly valued after run' call.
12ACMRAVOID2.6Bullish_prob 0 despite Daiwa $136 initiation; 4h fc_long -20.9% and 1wk fc_long -69% suggest post-run distribution.
13RSIAVOID2.5Every forecast horizon negative, bullish_prob 0, Yahoo cautionary coverage — screen fundamentals not confirmed by tape.
14SIMOAVOID1.8+209% YoY, 4h fc_long -76.8%, short interest jumped 80% — reversion trade, not a buy.
15ALMAVOID1.5PS 82.6, up 300% in a year, 1wk fc_long -96% — parabolic tungsten name that's screaming top.
16KNSAAVOID1.5Not in the multi-TF candidate set; only fundamental data — no confirmation available and up 135% YoY suggests waiting anyway.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord

⚠️ This AI-generated analysis is for informational purposes only and is not financial advice. Forecasts and scores are model outputs that can be wrong; markets involve substantial risk of loss. Do your own research.